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Abstract
Background: HIV infection remains a major US public health concern. While HIV-infected individuals now benefit from
earlier diagnosis and improved treatment options, progress is tempered by large numbers of newly diagnosed patients who
are lost to follow-up prior to disease confirmation and linkage to care.
Methodology: In the randomized, controlled USHER trial, we offered rapid HIV tests to patients presenting to a Boston, MA
emergency department. Separate written informed consent was required for confirmatory testing. In a secondary analysis,
we compared participants with reactive results who did and did not complete confirmatory testing to identify factors
associated with refusal to complete the confirmation protocol.
Principal Findings: Thirteen of 62 (21.0%, 95% CI (11.7%, 33.2%)) participants with reactive rapid HIV tests refused
confirmation; women, younger participants, African Americans, and those with fewer HIV risks, with lower income, and
without primary care doctors were more likely to refuse. We projected that up to four true HIV cases were lost at the
confirmation stage.
Conclusions: These findings underscore the need to better understand the factors associated with refusal to confirm
reactive HIV testing and to identify interventions that will facilitate confirmatory testing and linkage to care among these
populations.
Trial Registration: ClinicalTrials.gov NCT00502944; NCT01258582.
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Introduction
Expanded HIV screening has led more HIV-infected individ-
uals to be diagnosed earlier in the disease process [1–3]. However,
the goals of such efforts are often forestalled by continued difficulty
in confirming HIV diagnoses and linking patients to care [4,5].
Following the Center for Disease Control and Prevention’s 2006
guidelines for routine HIV screening [6], numerous reports have
documented successful testing programs in the emergency
department (ED), one of the guideline-targeted settings. Still,
HIV testing remains underutilized, and even when tests are
offered, patient refusal is a substantial barrier to optimal screening
[7–12].
The rapid screening tests frequently used in the ED require
Western Blot confirmation of reactive results. This is a critical step
in the diagnosis pathway, especially given numerous reports of
rapid test false positivity in various settings and in regions such as
New York City and San Francisco [13–17]. Yet patients are
frequently lost at the confirmatory step – a process that requires
obtaining consent in some settings, collecting a laboratory sample,
and conveying the results [18].This is especially true in fast-paced
urgent and emergent care settings [19]. In a screening program at
Howard University Hospital, only 39 of 130 patients with reactive
rapid tests presented for off-site confirmatory testing [20]. At
another urban university hospital ED in Washington, DC, half of
the 26 patients with reactive rapid tests were lost to follow-up [21].
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e53408Neither these studies, nor others to our knowledge, were able to
collect data on why patients did not obtain confirmatory testing.
It is critical to the testing mission to identify the individuals who
are more likely to be lost at this first step towards linkage to care.
In doing so, we can target efforts to improve rates of confirmatory
testing, and in turn, timely treatment. To this end, we conducted a
secondary analysis of a large clinical trial – the first to our
knowledge – to examine the frequency of failed confirmation as
well as demographic variables and HIV risk factors associated with
refusal to confirm a reactive rapid test. We then estimated the
number of missed opportunities to link to HIV care among those
who refused confirmatory testing.
Methods
Objectives
Our goal was to determine the rate of refusal to confirm reactive
rapid HIV tests in an urban emergency department, to
characterize the population who refused confirmation, and to
estimate the number of subjects with true positive HIV tests who
did not receive confirmatory testing.
Participants
The study was conducted within the Universal Screening for
HIV-infection in the Emergency Room (USHER) trial [22,23].
USHER was a randomized controlled trial of rapid HIV testing in
consenting adults who presented to the ED at Brigham and
Women’s Hospital (BWH), a tertiary academic medical center in
Boston, Massachusetts. Eligible patients (age 18–75, fluent in
English or Spanish, not receiving pre-natal care) were invited by a
bilingual counselor to enroll in an HIV testing trial. Patients were
consecutively enrolled between 8AM and midnight for at least 60
hours per week. Upon consenting to trial participation, subjects
were block randomized by age (,40 years old and $40 years old)
and sex.
Description of Investigation
In USHER Phase I (February 7, 2007 to July 9, 2008), enrolled
subjects were randomized to oral rapid testing offered by either an
ED provider or a dedicated HIV counselor [23]). With permission
of the institutional review board (IRB), subjects were enrolled and
randomized to testing by an ED provider or HIV counselor after
the Phase I stop date and before Phase II was approved (July 10,
2008 to May 1, 2009). In USHER Phase II (May 5, 2009 to
January 4, 2010) [22], HIV counselors offered testing to all
enrolled subjects who were then randomized by testing modality to
either the oral or fingerstick rapid test (OraQuickH ADVAN-
CETM Rapid HIV-1/2 Antibody Test, OraSure Technologies,
Inc. Bethlehem, PA). All data from Phase I, Phase II, and the
interim period were included in this analysis.
During the informed consent process for the rapid test, subjects
were told that ‘‘A small proportion of people may have a reactive
test. A REACTIVE test means you might have HIV infection.
To be sure, a second test must be done. It is important to know
that 3 out of 4 patients with a ‘‘reactive’’ test do NOT have HIV
infection.’’ After extensive discussion with the IRB, and with the
important goal of maintaining the informed consent at or below an
eighth grade reading level, we opted not to include additional
details about the role of site-specific performance data of the assay
or the observed local rate of disease.
Negative results were given to the patient as soon as they
became available. Reactive results were given by the HIV
counselor or ED provider after the initial medical encounter was
complete and a provisional plan had been made to admit, observe,
or discharge. This sequence assured that the patient’s chief
complaint was fully addressed before introducing the complication
of a reactive HIV test; the protocol did not permit discharge with
pending HIV test results.
Among patients with reactive test results, early study results
indicated that the positive predictive value of the oral rapid test
was lower than anticipated. Based on this finding, we hypothesized
that predictive value varied by test signal intensity and testers
began recording the darkness of the line for reactive rapid tests in
both phases of the study [24]. Since rapid test results were
maintained outside of the medical record for purposes of the trial,
the IRB required that individuals with reactive results provide a
second informed consent to complete the HIV confirmatory test
panel – Massachusetts law at that time required that this consent
be written. Subjects were documented to refuse HIV confirmatory
testing if they did not consent to standard ELISA and Western
Blot testing when offered by the HIV counselor or ED provider.
Upon conclusion of the encounter with the participant, the
counselor or provider documented that an HIV test was offered
and whether it was accepted or refused.
For those with reactive tests who consented to confirmation,
blood was then immediately drawn on-site to perform this panel,
which included 1) serum enzyme-linked immunoassay (ELISA), 2)
serum Western Blot, 3) CD4 count, and 4) plasma HIV-1 RNA.
All subjects with reactive rapid tests were scheduled to receive the
results of confirmatory studies within seven to ten days at a follow-
up appointment with a hospital infectious disease doctor. In the
interim, they were either seen by an HIV social worker in the ED
or scheduled to meet with one within two business days (depending
on time of presentation and who had administered the rapid test)
to facilitate follow-up and provide support.
All subjects with reactive tests were tracked based on whether
they were admitted and whether they attended their scheduled
appointments with the HIV social worker and HIV care provider.
For subjects opting for outside follow-up and confirmation, the
research assistant requested release of information and collected
the subjects’ contact information and follow-up plans to confirm
successful follow-up.
At time of enrollment, the HIV counselor collected demo-
graphic data including sex, age, race/ethnicity, primary language,
and education level. Subjects were also asked to complete an 86-
item self-administered questionnaire, either on paper or by audio
computer-assisted self-interview (ACASI) per their preference [25].
This questionnaire collected information on annual household
income, medical insurance status, access to a primary care
provider, HIV risk factors, HIV-related knowledge, self-perceived
need for HIV testing, and HIV testing history. The survey
addressed HIV risk behaviors through questions about sexual
practices and frequency of illicit drug and alcohol use (Alcohol Use
Disorders Identification Test [AUDIT]) [26]. Subjects were risk-
categorized based upon previously described definitions of risk [7]:
they were classified as having high sexual risk if they reported
being a male who has sex with males or noted having more than
one sexual partner in the last three months, having sex with a
person who was HIV-positive or had AIDS, having sex with
someone who has been incarcerated, or using a condom
sometimes or never. High alcohol risk was defined as an AUDIT
score of .8 [7] and high drug risk was defined as self-report of
using a single illicit drug ‘‘occasionally’’ or more often, or using
two or more drugs ‘‘once’’ or more often.
Participants were classified as having an HIV risk behavior if
they reported high risk in at least one of these three categories
(sexual, drug, and alcohol risk). Participants who denied engaging
in any of these risk factors were categorized as not having any risk
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behaviors, those data were considered ‘‘missing.’’
Ethics
Written informed consent was received from all participants and
all clinical investigation was conducted according to the principles
expressed in the Declaration of Helsinki. The USHER trial was
approved by the Partners Human Research Committee (protocol
2006P-000136) and overseen by an Institutional Review Board.
Statistical Methods
A secondary analysis was performed on data from USHER
Phases 1 and 2 and the interim phase. The outcome of interest was
refusal to confirm a reactive rapid test. The association of
demographic variables and HIV risk factors with confirmation
refusal was examined in bivariate analyses. Means and standard
deviations were calculated for continuous variables and frequen-
cies were calculated for categorical variables. Fisher’s exact test
and t-tests were used to compare confirmers and refusers. These
comparisons were exploratory in nature so no adjustment was
made for multiple comparisons. Due to the small number of
refusers, multivariable models were not examined. Therefore, we
could not adjust for potential confounders.
Due to high rates of false positivity with the rapid test in the
setting of low HIV prevalence at our site and others, we could not
assume that all patients with reactive rapid tests were truly HIV
infected [13–17]. So, we estimated the number of cases of true
HIV infection missed among those who refused confirmatory
testing. We used two approaches: first, we calculated the
proportion of true positives and the associated exact 95%
confidence interval among those who did confirm. We used this
value to estimate the number of true cases of HIV infection missed
in those who failed to confirm. For the second approach, we
stratified the sample by intensity of the line for the rapid test
(darker than internal control, lighter than internal control, line
intensity missing). It has been shown that positive predictive value
improves substantially when reactive results are stratified by line
intensity [24]. We calculated the proportion of true positives and
the associated exact 95% confidence interval among those who
confirmed within each group, then estimated the expected number
of HIV-infected participants among those who refused confirma-
tory testing by multiplying the estimated probability of being a true
positive within each line intensity group by the number of non-
confirmers in each line intensity group.
All analyses were conducted using SAS software version 9.2
(SAS Institute, Cary, NC).
Results
Between February 7, 2007 and January 4, 2010, 27,441 patients
at the BWH ED were screened for enrollment and 8,882 patients
were enrolled in USHER-related activities [23]. The most
frequently documented reason for ineligibility was age
(n=6,396; 23.3% of all screened). An additional 12.3% of patients
were admitted or discharged before USHER enrollment could be
completed (n=3,381).
Among 4,056 subjects with valid oral (3,508) or fingerstick (548)
test results, 62 had reactive tests (1.5%). Fifty-nine of the subjects
with reactive tests received an oral test while three of them
received a fingerstick test. Among USHER participants with
reactive tests, 49 (79.0%) agreed to confirmatory testing–47 out of
59 (79.7%) of patients who received an oral test and 2 out of 3
(66.7%) patients who received a fingerstick test confirmed. The
other 13 subjects refused explicitly. Of the 49 who confirmed, 9
(18.4%) had confirmatory studies indicating true HIV-infection,
for an overall undiagnosed HIV prevalence of 9/4,056 or 0.22%
(95% CI: 0.10–0.42) (Figure 1). Seven of the nine subjects who
confirmed and tested positive attended a follow-up appointment,
compared to none of the 13 who refused confirmatory testing.
Comparing Subjects who did and did not Complete
Confirmatory Testing
Subjects who declined confirmatory testing more frequently
completed the self-administered questionnaire (12/13, 92.3%)
compared to subjects who accepted confirmatory testing (37/49,
75.5%). Among participants with questionnaire data, subjects who
declined confirmatory testing were younger on average than those
who accepted (40.0 vs 44.9) (Table 1). Females were more likely to
decline confirmatory testing (28.6%) than males (11.1%). Among
respondents, subjects with incomes greater than $50,000 were less
likely to refuse confirmatory testing (15.4%) than those with lower
incomes (29.6%) while those with a primary care provider were
also less likely to refuse (22.2%) than those without one (33.3%).
History of prior testing was positively associated with refusal to
confirm: of the 30 who reported being previously tested, 8 (26.7%)
declined confirmatory testing; and of the 12 who reported never
being previously tested, 1 (8.3%) declined confirmation. Subjects
in low and high sexual risk categories based on our risk definitions
were similarly likely to refuse confirmation (20.0% vs 20.6%). Both
low and high risk groups were less likely to refuse than those who
did not answer the sexual risk questions (40.0%). 18.9% of subjects
in the low alcohol risk category refused confirmatory testing versus
none in the high risk category. Subjects in the low drug risk
category were also more likely to refuse (29.4%), compared to
those in the high risk category (5.6%) – this difference reached
statistical significance (p=0.032).
Estimating Number of True HIV Cases among those who
Refused Confirmatory Testing
Using the proportion of true positives among those who did
confirm (18.4%, (95% CI: 8.8% –32.0%)), we estimated that 2.4 of
the 13 USHER participants who refused to confirm were likely to
be HIV infected (95% CI: 1.1–4.2).
Overall, tests with dark lines were recorded for 11 (17.7%)
participants, light lines were recorded for 34 (54.8%) participants,
and line intensity was not recorded for 17 participants (27.4%)
(Table 2). (Line intensity was not reported until its correlation with
true positivity was suspected. Therefore, the majority of missing
Figure 1. Outcomes of subjects with reactive results on HIV
rapid test (1.5% of total tested).
doi:10.1371/journal.pone.0053408.g001
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Variable Subcategory Confirmed (N=49) Unconfirmed (N=13) p-value
Age, years (mean (std dev)) 44.9 (14.9) 40.0 (10.4) 0.275
Sex 0.122
Male 24 (88.9%) 3 (11.1%)
Female 25 (71.4%) 10 (28.6%)
Race/Ethnicity 0.127
Non-Hispanic White 18 (78.3%) 5 (21.7%)
Non-Hispanic Black 12 (63.2%) 7 (36.8%)
Hispanic 15 (93.8%) 1 (6.3%)
Other 4 (100.0%) 0 (0%)
Education, more than high school 1.000
No 23 (79.3%) 6 (20.7%)
Yes 26 (78.8%) 7 (21.2%)
Income.$50,000 0.741
No 19 (70.4%) 8 (29.6%)
Yes 11 (84.6%) 2 (15.4%)
Missing
a 7 (77.8%) 2 (22.2%)
Has a primary care provider 0.649
No 4 (66.7%) 2 (33.3%)
Yes 28 (77.8%) 8 (22.2%)
Missing
a 5 (71.4%) 2 (28.6%)
HIV Knowledge, 17 or 18 items correct 0.632
No 29 (78.4%) 8 (21.6%)
Yes 5 (71.4%) 2 (28.6%)
Missing
a 3 (60.0%) 2 (40.0%)
Ever been tested for HIV 0.203
No 11 (91.7%) 1 (8.3%)
Yes 22 (73.3%) 8 (26.7%)
Missing
a 4 (57.1%) 3 (42.9%)
Perceived need of testing 0.885
No 12 (80.0%) 3 (20.0%)
Yes 21 (72.4%) 8 (27.6%)
Missing
a 4 (80.0%) 1 (20.0%)
Sexual Risk 0.392
No 4 (80.0%) 1 (20.0%)
Yes 27 (79.4%) 7 (20.6%)
Missing
a 6 (60.0%) 4 (40.0%)
Alcohol Risk 0.062
No 30 (81.1%) 7 (18.9%)
Yes 3 (100.0%) 0 (0%)
Missing
a 4 (44.4%) 5 (55.6%)
Illicit Drug Use Risk 0.032
No 12 (70.6%) 5 (29.4%)
Yes 17 (94.4%) 1 (5.6%)
Missing
a 8 (57.1%) 6 (42.9%)
Risk Behavior Category 0.058
No risk reported 0 (0%) 1 (100.0%)
.=1 Risk reported 31 (81.6%) 7 (18.4%)
Missing risk 6 (60.0%) 4 (40.0%)
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subjects who did confirm, those with dark-lined tests were much
more likely to be true positives than others: 6/7 subjects with dark-
lined tests were true positives (85.7%, 95% CI: (42.1%–99.6%)),
3/13 with line intensity not recorded were true positives (23.1%,
95% CI: (5.0%–53.8%)) and none of the 29 subjects with light-
lined tests were true positives (0%, 95% CI: (0%–11.9%)). Among
those who refused confirmatory testing, a dark line was recorded
for 4 participants, a light line was recorded for 5 participants, and
line intensity was missing for 4 participants. By multiplying the
likelihood of true positivity in each group by the number of non-
confirmers in that group, we predicted that 4.4 (95% CI: 1.9–6.7)
of the 13 USHER participants who refused to confirm were likely
to be HIV infected.
Discussion
Among the 4,056 patients who received HIV rapid tests with
valid results in the USHER trial, 62 had reactive results. Of these,
49 had confirmatory testing and nine in this group were found to
be true positive. The remaining 13 refused confirmatory testing.
Women, African Americans, and those self-reporting less HIV risk
were more likely to refuse confirmation. We estimated that,
depending on the prediction methods used, two to four additional
cases of true HIV would have been identified if those 13
participants had agreed to confirmatory testing.
In 2006, the CDC issued guidelines for routine HIV testing with
the critical goals to identify and counsel more individuals with
unrecognized HIV infection and to link them to care [6].
However, as the USHER trial experience demonstrates, barriers
to this goal remain, even once the initial screening test is offered
and performed.
In some respects, refusal of confirmatory testing is a similar
phenomenon to refusal of the initial screening test. Indeed, the
demographic and risk profile of non-confirmers reported here
parallels others’ findings on individuals who refuse HIV screening
in general [27,28]. Previously published multivariate analyses from
the USHER trial [7] and elsewhere [29] have shown that women
and patients with annual household incomes of .$50,000 are
more likely to refuse testing, as are individuals who report not
engaging in HIV risk behaviors, those who have been tested
previously, and those who do not perceive a need for testing. In a
series of in-depth interviews with patients who refused HIV testing
in the ED setting, cited reasons included: a recent prior test, the
perception of low risk, and concerns about distraction from their
chief complaint, about the implications for a relationship, and
about the documentation of positive HIV status [30].
The decision to confirm a reactive screening test is a distinct
phenomenon that incurs the psychological burden of being one
step closer to a potential new HIV diagnosis. A key question is the
degree to which this burden affects patients’ decisions not to
confirm the initial screening result. Individuals who refuse at this
stage may be troubled by the implications of a true HIV diagnosis
and seek escape. This is corroborated by earlier estimates, prior to
scaling up testing efforts, of an 8.1 year lag between acquiring HIV
and initial presentation to care [31].
In our study, women and African Americans were less likely to
seek confirmatory testing. Though some women may refuse due to
their perception of low risk, women are in fact a significant
percentage of the U.S. HIV-infected population (25% of those
living with HIV infection in 2008) [32,33], and African American
females in particular have disproportionate rates of new infection
[33]. Women in particular, in the absence of pregnancy, may be
more likely to refuse confirmatory testing because of concerns
Table 2. Estimating the number of true HIV cases missed.
Confirmers Non-Confirmers
Line Intensity Total (N) % True Positive (95% CI) Total (N) Estimated # of true positives (95% CI)
Darker than internal control 7 85.7% (42.1%–99.6%) 4 3.4 (1.7–4.0)
Lighter than internal control 29 0% (0%–11.9%) 5 0 (0–0.6)
Missing 13 23.1% (5.0%–53.8%) 4 0.9 (0.2–2.2)
Total 13 4.4 (1.9–6.7)
doi:10.1371/journal.pone.0053408.t002
Table 1. Cont.
Variable Subcategory Confirmed (N=49) Unconfirmed (N=13) p-value
No questionnaire 12 (92.3%) 1 (7.7%)
Line Intensity 0.298
Darker than internal control 7 (63.6%) 4 (36.4%)
Lighter than internal control 29 (85.3%) 5 (14.7%)
Missing
b 13 (76.5%) 4 (23.5%)
Test Type 0.513
Fingerstick 2 (66.7%) 1 (33.3%)
Oral 47 (79.7%) 20.3%)
aExcludes participants with no participant questionnaire completed (Twelve subjects in the Confirmed group and one subject in the Unconfirmed group).
bLine intensity was not reported until its correlation with true positivity was suspected. Therefore, the majority of missing data were from early reactive results.
doi:10.1371/journal.pone.0053408.t001
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confirmatory testing because subsequent care might compete with
other needs such as childcare and personal subsistence [34,35]. In
one study, white women were the most likely not to seek care for
an HIV diagnosis in a timely fashion, followed by minority women
[36].
All patients may be concerned about having a positive HIV
status recorded in their medical charts (this documentation may
not occur with a reactive rapid test alone) and the implications for
health insurance and employment status. African American
patients in particular have been reported to distrust the medical
system, particularly when the consequences of the confirmatory
testing may have long-term implications [34].
Some participants may have declined confirmatory testing
because they worried about accessing follow-up care. Those who
reported having a primary care provider were somewhat less likely
to refuse confirmatory testing (22.2%) than those without a
primary care provider (33.3%). However, 8 out of 12 non-
confirmers who responded to our survey noted that they had a
primary care physician, suggesting that this does not guarantee
easy or affordable access to the expensive anti-retroviral drugs
needed for life-sustaining care and further emphasizing the
importance of parallel HIV screening efforts in the primary care
setting [37]. Subjects reporting incomes greater than $50,000 were
more likely to confirm reactive results than those with lower
incomes; perhaps subjects with higher incomes felt better-
equipped to handle the repercussions of a true positive test.
In the USHER trial, subjects who had previously been tested for
HIV were more likely to refuse HIV rapid testing than those who
had not previously been tested [7]. Similarly, in our analysis,
among the subjects who had a reactive rapid test, those who had
been previously tested were also more likely to refuse confirmatory
testing, perhaps because they felt reassured by a prior negative test.
Patients may also decline confirmatory testing because of its
inconvenience and their desire to leave the ED. Some studies
document that ED patients felt that rapid testing did not delay
their medical care (92.5%) or divert attention from the reason for
their ED visit (94.1%) [38]. However, respondents may have
overestimated their acceptance of this confirmatory test, under the
assumption that they would not require it. It is also possible that
they refused based on knowledge of the oral rapid test’s low
specificity: Fifty-nine out of 62 individuals with reactive tests had
received an oral test, and they learned in the informed consent
process that 3 out of 4 reactive oral rapid tests are false positives.
But despite the low specificity of the oral test, a reactive oral test
still increases the pre-test probability of infection prior to
confirmatory testing by around 300 fold (from 0.078% to 25%),
certainly enough to merit follow-up testing [39,40].
In USHER, most subjects with reactive rapid HIV tests and
positive confirmatory testing (7/9) attended their first follow-up
appointment as scheduled by the USHER team. Unfortunately, all
participants refused requests to inquire about confirmatory results
outside the study context (e.g. by calling their primary care
providers or by contacting other potential sources of confirmation).
As such, we were not able to determine if these subjects sought this
testing or care elsewhere.
Of note, subjects who refused confirmatory testing were more
likely to agree to complete the 86-item questionnaire compared to
those who accepted confirmatory testing (92.3% vs 75.5%). This,
and the fact that all subjects in the reactive test group, by
definition, agreed to initial testing, suggests that subjects did not
refuse confirmatory testing simply because they did not want to
participate in research. Rather, they more likely refused due to
anxiety surrounding a possible diagnosis or another factor specific
to the confirmatory process. We cannot rule out, however, that the
Massachusetts requirement for written, rather than verbal, consent
at each step did not have an impact on subjects’ willingness to
undergo confirmatory testing; we believe that passage of the 2012
Massachusetts law allowing for verbal consent may facilitate
consenting efforts.
In compliance with the IRB, the USHER trial required patients
to provide separate consent for confirmatory testing, unlike other
testing programs which are often able to obtain consent for rapid
and confirmatory testing at the same time. The second consent
hurdle allowed us a rare look at the most proximal point in linkage
to care and to identify individuals most likely to be left behind at
this important step. Of note, some EDs have bypassed this step
entirely by using either sequential rapid tests [19] or rapid testing
on venipuncture specimens, which allow for confirmatory testing
on the same sample [41]. Based on the predictive model, two to
four true diagnoses of HIV were lost to follow-up. These
additional diagnoses would have increased our total number of
true positives by up to 49% (4.4/9). This finding, and our
characterization of non-confirmers based on demographics, risk
factors, and HIV knowledge, underscores the importance of
targeting these groups in the testing process.
Limitations
Results of this study should be interpreted within the context of
its limitations. This secondary analysis included a small number of
patients with reactive rapid tests, which reflects the relatively low
prevalence of HIV and increasing frequency of testing in the
Boston area. As a result, we had limited power to detect
statistically significant differences between confirmers and refusers
(Table 1). The high false positive rates associated with oral rapid
testing in the study have been reported elsewhere, in the context of
the USHER trial and others [15]; the rapid test manufacturer has
since improved the test’s specificity, so confirmatory testing may
have been viewed more favorably by subjects if the study had been
performed more recently [42]. In the consent process, we did not
routinely explain the impact of site-specific assay performance and
disease prevalence on the rapid test’s positive predictive value.
In addition, thirteen of the sixty-two participants (21%) refused
the questionnaire; among those who completed it, many omitted
specific questions. Thus, our capacity to address all of the
behavioral associations with refusal was limited. Additionally, if
the participants who refused the questionnaire or omitted specific
questions are different than those who answered the questions,
specifically if non-response is related to refusal to confirm, our
results could be biased. Furthermore, our paper is limited to
demographic and risk factor description of those who refused to
confirm; we were unable to obtain direct data as to why
participants refused. However, considering the sensitive nature
of the questionnaire content, the relatively low prevalence of HIV,
and the difficulty in connecting with the population under
consideration, we had greater success than has been previously
reported. Further studies should be performed to better charac-
terize why certain subjects may not confirm reactive rapid HIV
tests or seek follow-up care.
We estimated the number of cases of true HIV missed in those
refusing confirmatory testing by two methods, the first of which
used the proportion of true positives in those that did confirm.
This method assumed that the rate of true HIV infection is similar
in the confirmers and non-confirmer groups and therefore may
have produced a conservative estimate, as the non-confirmer
group likely had a higher rate of true infection. The small number
of cases limited our ability to explore multivariable models to
predict the number of cases missed.
Refusal to Confirm Reactive Rapid HIV Tests
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e53408In this study, we found that younger subjects, women, African
Americans, and those from lower self-reported HIV risk catego-
ries, with lower incomes, and without primary care providers were
more likely to disengage from the linkage to care process by
refusing confirmatory testing. We predicted that two to four cases
of true HIV were not diagnosed as a result of refused confirmatory
testing. These findings suggest the need for further characteriza-
tion of at-risk populations and interventions targeting these
populations in order to strengthen the very first link in the chain
of effective HIV care.
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